- Email: [email protected]
Plasma adiponectin levels in obese patients with essential hypertension and its affecting factors
Abstracts
decreased LVMI and inhibited local inflammatory cell infiltration in cardiac tissue, and combination therapy inhibits further compared with each monotherapy. The serum levels of hs-CRP, TNF-α, IL-1β were significantly higher in SHR control group than that of WKY control group (each P<0.05). The serum levels of hs-CRP and TNF-α in the amlodipine or atorvastatin administration group significantly dropped compared with the SHR control group (each P<0.05), and those in the combined drug group dropped even further than those in the single drug group (P<0.05). Both amlodipine and atorvastatin slightly, but not significantly, decreased serum IL-1β concentration (each P>0.05), and combination therapy significantly decreased serum IL-1β concentration compared with the SHR control group (P<0.05). Compared with that of same aged WKY group, the protein expressions of TNF-α, IL-1β were proven to be enhanced in SHR control group by western blot (each P<0.05). Furthermore, all the proteins were reduced markedly after amlodipine or atorvastatin intervention (each P<0.05), and that of the combined drug group was even lower than that of the single drug groups (each P < 0.05). Conclusions: By way of down-regulation for systemic inflammation and myocardial TNF-α, IL-1β, amlodipine and atorvastatin may reverse cardiac hypertrophy. Amlodipine combined with atorvastatin may have additive effects on inhibition of myocardial inflammatory response. doi:10.1016/j.ijcard.2009.09.487
CJ-2009-C-014 The effects of combined amlodipine and atorvastatin on the balance of myocardial MMPs/TIMPs system in SHR J.C. LU, W. CUI, F. LIU, D.M. LIU, R.Q. XIE, X.H. YANG, G.Q. GU The department of cardiology, the second hospital of Hebei Medical University, Shijiazhuang, China Objective: To explore the effect of amlodipine, atorvastatin, and their combination on the balance of myocardial MMPs/TIMPs system, by investigating the changes of MMP-2, MMP-9 as well as TIMP-1, TIMP-2 expression in SHR. Methods: 36-week-old SHR were randomly allocated into four groups: a vehicle-treated control group; an amlodipine (10 mg/ kg/day)-treated group; an atorvastatin (10 mg/kg/day)-treated group; and a group treated with a combination of amlodipine and atorvastatin (both at 10 mg/kg/day). In addition, WKY rats were chosen as control group of normal blood pressure. Drugs were administered by oral gavage every morning for a period of 12 weeks before hearts were harvested for analysis. Geltin zemography was used to evaluate the activity of MMP-2 and MMP-9. RT-PCR was used to observe the gene expression of MMP-2, MMP-9 as well as TIMP-1, TIMP-2. Results: Gelatin zemography showed the activity of MMP-2, MMP-9 was higher in SHR than that in WKY (each P < 0.05). Either amlodipine or atorvastatin lowered the activity of MMP2 and MMP-9 of SHR (each P < 0.05); furthermore, combination therapy had the best lowering effect (P < 0.05). RT-PCR showed the mRNA expression levels of MMP-2 and MMP-9 in SHR were all significantly increased in contrast to that in WKY (each P < 0.05). The mRNA expression levels of MMP-2 and MMP-9 in the amlodipine or atorvastatin administration groups were significantly reduced compared with that in SHR group (each P<0.05). The mRNA expression levels of MMP-2 and MMP-9 in the combined amlodipine and atorvastatin group were even lower than that in the single amlodipine or atorvastatin groups (each P<0.05). The mRNA expression levels of TIMP-1 in SHR were significantly increased in contrast to that of WKY (each P<0.05). Nevertheless, either amlodipine or atorvastatin, as well as combination therapy did not alter myocardial TIMP-1 levels in SHR (each P>0.05). The mRNA expression levels of TIMP-2 in SHR were not different from that in WKY (each P>0.05). Either amlodipine or atorvastatin as well as combination therapy did not alter myocardial TIMP-2 levels in SHR (each P>0.05). Conclusion: Both amlodipine and atorvastatin decreased the activity and mRNA expression levels of MMP-2 and MMP-9 in SHR, and combination therapy
S141
had the best lowering effects. Thereby, by way of maintaining the balance of MMP-2/TIMP-2 and MMP-9/TIMP-1, amlodipine and atorvastatin may significantly relieve hypertensive interstitial fibrosis. doi:10.1016/j.ijcard.2009.09.488 CJ-2009-C-015 Plasma adiponectin levels in obese patients with essential hypertension and its affecting factors H. JIANG, H. XI, T. LV, H.Y. HU VIP Department, the First Affiliated Hospital of Dalian Medical University, Dalian, China Objective: To investigate the correlation between of plasma adiponectin and other parameters by detecting plasma adiponectin levels in normotensive (NT) and essential hypertensive (EHP) male patients with or without obesity. Methods: Fifty-four patients were enrolled in the EHP group, among them 31 obese patients with a BMI≥25 kg/m2. Seventy patients were enrolled in the NT group, 30 of these were obese. Fasting plasma adiponectin levels were measured in each patient. Results: (1) The adiponectin level in the EHP group (7.48±3.4 μg/mL) was significantly lower than that in the NT group (10.57±4.73 μg/mL, P<0.01). (2) The plasma adiponectin levels were lower in the obese EHP group (6.5± 2.95 μg/mL) than in the other three subgroups (P<0.05). (3) Multiple linear related analysis showed significantly negative correlations between plasma adiponectin and waistline circumference (WC), body mass index (BMI), blood pressure (BP), triglyceride (TG), blood serum insulin level (FINS) and homeostasis analog insulin resistance index (HOMA-IR), and positive correlations between plasma adiponectin and high density lipoprotein cholesterol (HDL-C) levels. BP, WC, BMI, HOMA-IR were the most independent factors that affecting the level of plasma adiponectin. Conclusion: (1) The plasma adiponectin levels were lower in patients with EHP, and even lower in patients with obesity and EHP. (2) There was an independent correlation between the levels of plasma adiponectin and blood pressure. doi:10.1016/j.ijcard.2009.09.489 CJ-2009-C-016 MicroRNA-155 Regulates Angiotensin II Type 1 Receptor Expression and Phenotypic Differentiation in Vascular Adventitial Fibroblasts C.C. XUa,1, L. ZHENGa,1, W.D. CHENa, C.C. RUANb, D.L. ZHUa,b,c, P.J. GAOa,b,c, ⁎ Shanghai Key Laboratory of Vascular Biology at Ruijin Hospital and Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine, Shanghai, China b Laboratory of Vascular Biology, Institute of Health Sciences, Shanghai Institute for Biological Science (SIBS), Chinese Academy of Sciences, Shanghai, China c State Key Laboratory of Medical Genomics, Shanghai, China a
Objectives: MicroRNAs (miRNAs) are genomically-encoded small RNAs which can negatively regulate target gene expression at the posttranscriptional level. MiRNA-155 is a typical multifunctional miRNA, however, little is known about its effects on the cardiovascular diseases. The aim of the present study was to explore the potential role of miR-155 on angiotesion II type 1 receptor (AT1R) expression regulation and phenotypic differentiation in rat aortic adventitial fibroblasts (AFs). Methods: MiRanda, TargetScan and PicTar were used to predict miRNAs and target genes. AFs were transfected with pSUPER/miR-155 by liposome. The expression levels of miR-155 in AFs were detected by real-time RT-PCR using a specific stem-loop reverse transcriptase primer. The phenotypic differentiation of AFs was induced by Ang II (10-7 mol/L) and TGF-β1
decreased LVMI and inhibited local inflammatory cell infiltration in cardiac tissue, and combination therapy inhibits further compared with each monotherapy. The serum levels of hs-CRP, TNF-α, IL-1β were significantly higher in SHR control group than that of WKY control group (each P<0.05). The serum levels of hs-CRP and TNF-α in the amlodipine or atorvastatin administration group significantly dropped compared with the SHR control group (each P<0.05), and those in the combined drug group dropped even further than those in the single drug group (P<0.05). Both amlodipine and atorvastatin slightly, but not significantly, decreased serum IL-1β concentration (each P>0.05), and combination therapy significantly decreased serum IL-1β concentration compared with the SHR control group (P<0.05). Compared with that of same aged WKY group, the protein expressions of TNF-α, IL-1β were proven to be enhanced in SHR control group by western blot (each P<0.05). Furthermore, all the proteins were reduced markedly after amlodipine or atorvastatin intervention (each P<0.05), and that of the combined drug group was even lower than that of the single drug groups (each P < 0.05). Conclusions: By way of down-regulation for systemic inflammation and myocardial TNF-α, IL-1β, amlodipine and atorvastatin may reverse cardiac hypertrophy. Amlodipine combined with atorvastatin may have additive effects on inhibition of myocardial inflammatory response. doi:10.1016/j.ijcard.2009.09.487
CJ-2009-C-014 The effects of combined amlodipine and atorvastatin on the balance of myocardial MMPs/TIMPs system in SHR J.C. LU, W. CUI, F. LIU, D.M. LIU, R.Q. XIE, X.H. YANG, G.Q. GU The department of cardiology, the second hospital of Hebei Medical University, Shijiazhuang, China Objective: To explore the effect of amlodipine, atorvastatin, and their combination on the balance of myocardial MMPs/TIMPs system, by investigating the changes of MMP-2, MMP-9 as well as TIMP-1, TIMP-2 expression in SHR. Methods: 36-week-old SHR were randomly allocated into four groups: a vehicle-treated control group; an amlodipine (10 mg/ kg/day)-treated group; an atorvastatin (10 mg/kg/day)-treated group; and a group treated with a combination of amlodipine and atorvastatin (both at 10 mg/kg/day). In addition, WKY rats were chosen as control group of normal blood pressure. Drugs were administered by oral gavage every morning for a period of 12 weeks before hearts were harvested for analysis. Geltin zemography was used to evaluate the activity of MMP-2 and MMP-9. RT-PCR was used to observe the gene expression of MMP-2, MMP-9 as well as TIMP-1, TIMP-2. Results: Gelatin zemography showed the activity of MMP-2, MMP-9 was higher in SHR than that in WKY (each P < 0.05). Either amlodipine or atorvastatin lowered the activity of MMP2 and MMP-9 of SHR (each P < 0.05); furthermore, combination therapy had the best lowering effect (P < 0.05). RT-PCR showed the mRNA expression levels of MMP-2 and MMP-9 in SHR were all significantly increased in contrast to that in WKY (each P < 0.05). The mRNA expression levels of MMP-2 and MMP-9 in the amlodipine or atorvastatin administration groups were significantly reduced compared with that in SHR group (each P<0.05). The mRNA expression levels of MMP-2 and MMP-9 in the combined amlodipine and atorvastatin group were even lower than that in the single amlodipine or atorvastatin groups (each P<0.05). The mRNA expression levels of TIMP-1 in SHR were significantly increased in contrast to that of WKY (each P<0.05). Nevertheless, either amlodipine or atorvastatin, as well as combination therapy did not alter myocardial TIMP-1 levels in SHR (each P>0.05). The mRNA expression levels of TIMP-2 in SHR were not different from that in WKY (each P>0.05). Either amlodipine or atorvastatin as well as combination therapy did not alter myocardial TIMP-2 levels in SHR (each P>0.05). Conclusion: Both amlodipine and atorvastatin decreased the activity and mRNA expression levels of MMP-2 and MMP-9 in SHR, and combination therapy
S141
had the best lowering effects. Thereby, by way of maintaining the balance of MMP-2/TIMP-2 and MMP-9/TIMP-1, amlodipine and atorvastatin may significantly relieve hypertensive interstitial fibrosis. doi:10.1016/j.ijcard.2009.09.488 CJ-2009-C-015 Plasma adiponectin levels in obese patients with essential hypertension and its affecting factors H. JIANG, H. XI, T. LV, H.Y. HU VIP Department, the First Affiliated Hospital of Dalian Medical University, Dalian, China Objective: To investigate the correlation between of plasma adiponectin and other parameters by detecting plasma adiponectin levels in normotensive (NT) and essential hypertensive (EHP) male patients with or without obesity. Methods: Fifty-four patients were enrolled in the EHP group, among them 31 obese patients with a BMI≥25 kg/m2. Seventy patients were enrolled in the NT group, 30 of these were obese. Fasting plasma adiponectin levels were measured in each patient. Results: (1) The adiponectin level in the EHP group (7.48±3.4 μg/mL) was significantly lower than that in the NT group (10.57±4.73 μg/mL, P<0.01). (2) The plasma adiponectin levels were lower in the obese EHP group (6.5± 2.95 μg/mL) than in the other three subgroups (P<0.05). (3) Multiple linear related analysis showed significantly negative correlations between plasma adiponectin and waistline circumference (WC), body mass index (BMI), blood pressure (BP), triglyceride (TG), blood serum insulin level (FINS) and homeostasis analog insulin resistance index (HOMA-IR), and positive correlations between plasma adiponectin and high density lipoprotein cholesterol (HDL-C) levels. BP, WC, BMI, HOMA-IR were the most independent factors that affecting the level of plasma adiponectin. Conclusion: (1) The plasma adiponectin levels were lower in patients with EHP, and even lower in patients with obesity and EHP. (2) There was an independent correlation between the levels of plasma adiponectin and blood pressure. doi:10.1016/j.ijcard.2009.09.489 CJ-2009-C-016 MicroRNA-155 Regulates Angiotensin II Type 1 Receptor Expression and Phenotypic Differentiation in Vascular Adventitial Fibroblasts C.C. XUa,1, L. ZHENGa,1, W.D. CHENa, C.C. RUANb, D.L. ZHUa,b,c, P.J. GAOa,b,c, ⁎ Shanghai Key Laboratory of Vascular Biology at Ruijin Hospital and Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine, Shanghai, China b Laboratory of Vascular Biology, Institute of Health Sciences, Shanghai Institute for Biological Science (SIBS), Chinese Academy of Sciences, Shanghai, China c State Key Laboratory of Medical Genomics, Shanghai, China a
Objectives: MicroRNAs (miRNAs) are genomically-encoded small RNAs which can negatively regulate target gene expression at the posttranscriptional level. MiRNA-155 is a typical multifunctional miRNA, however, little is known about its effects on the cardiovascular diseases. The aim of the present study was to explore the potential role of miR-155 on angiotesion II type 1 receptor (AT1R) expression regulation and phenotypic differentiation in rat aortic adventitial fibroblasts (AFs). Methods: MiRanda, TargetScan and PicTar were used to predict miRNAs and target genes. AFs were transfected with pSUPER/miR-155 by liposome. The expression levels of miR-155 in AFs were detected by real-time RT-PCR using a specific stem-loop reverse transcriptase primer. The phenotypic differentiation of AFs was induced by Ang II (10-7 mol/L) and TGF-β1